On October 12, 2017, Patil, Rakesh Ishwar; Gunjal, Amol Pandurang; Verma, Jeevan; Kumar, Puneet; Rai, Santosh Kumar; Rai, Himanshu; Kumar, Anil published a patent.Synthetic Route of 364-12-5 The title of the patent was Preparation of heterocyclic compounds as GPR119 agonist for treatment of metabolic disorders. And the patent contained the following:
The invention relates to novel compounds of formula I as GPR119 agonist, compositions containing such compounds and method of their preparation which are useful for the prevention or treatment of metabolic disorders including diabetes mellitus type I and type II. I [wherein X1, X2, X3, X4, and X5 independently = N, O, S, or CH; R1 and R2 independently = H, O, C1-6alkyl, amino, etc.; A = tetrazol-1-ylphenyl-, 4-dimethylaminocarbonyl-Ph, 1-benzyl-piperazin-4-yl, etc.; B = morpholin-4-ylcarbonyl-Ph, -CH2OH, 4-cyano-Ph, etc.; n = 0, 1, 2, or 3] or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof, are claimed and exemplified. Example compound II was prepared from the oxidation of the corresponding sulfanyl intermediate in 37.62% yield. Exemplified I were evaluated for antidiabetic activity using an oral glucose tolerance test in mice and Sprague-Dawley rats from which II demonstrated dose-dependent reduction of glucose at 3mpk and 10mpk. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Synthetic Route of 364-12-5
The Article related to heterocyclic compound preparation gpr119 metabolic disease diabetes, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 364-12-5
Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com